| Literature DB >> 27338374 |
Pin-Jia Wang1,2, Cheng-Bin Xie3, Feng-Hui Sun4, Li-Juan Guo5, Min Dai6, Xi Cheng7, Yong-Xin Ma8.
Abstract
Staphylococcus epidermidis, especially methicillin-resistant strains, may be the source of surgical site infections and may be a reservoir of staphylococcal cassette chromosome mec (SCCmec) for S. aureus. The aim of this study was to investigate the prevalence of methicillin-resistant S. epidermidis (MRSE) on the abdominal skin of females before laparotomy and determine the molecular characteristics and antimicrobial susceptibility patterns of these isolates. MRSE was found in 54 of 157 isolates based on mecA gene detection, and there was no difference in icaA gene carriage rate between MRSE and methicillin-susceptible S. epidermidis (MSSE) isolates. Antimicrobial susceptibility profiles were determined by broth microdilution antimicrobial susceptibility testing according to the latest CLSI manuals. All MRSE isolates had unfavorable antimicrobial susceptibility patterns. Twenty-three MRSE strains (42.6%) were multi-drug resistant. SCCmec typing and pulsed field gel electrophoresis (PFGE) typing was performed. Thirty-nine (72.2%) had a single SCCmec type, whereas 1.9% had two types. Fourteen strains (25.9%) were non-typeable (NT). The most frequent MRSE genotype was SCCmec type IVa. High diversity with PFGE patterns was obtained for MRSE, and there were no isolates exhibiting identical pulsotype. The results confirm that methicillin-resistant strains are frequently present among S. epidermidis on the abdominal skin of females before laparotomy. Moreover, resistance profiles seem to have no association with the SCCmec types or PFGE types for most common antibiotics.Entities:
Keywords: PFGE; SCCmec; antibiotic resistant; laparotomy; methicillin-resistant Staphylococcus epidermidis; skin
Mesh:
Substances:
Year: 2016 PMID: 27338374 PMCID: PMC4926520 DOI: 10.3390/ijms17060992
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Resistance profiles of 54 methicillin-resistant S. epidermidis (MRSE) isolates and 103 methicillin-susceptible S. epidermidis (MSSE) isolates.
| Antibiotics | MSSE ( | MRSE ( | MIC Range | ||||
|---|---|---|---|---|---|---|---|
| %R(n) | MIC50 | MIC90 | %R(n) | MIC50 | MIC90 | ||
| Penicillin G | 85.4(88) | 16 | 16 | 96.3(52) | 16 | 16 | 0.03–16 |
| Ampicillin | 84.5(87) | 16 | 16 | 96.3(52) | 16 | 16 | 0.25–16 |
| Oxacillin | 0(0) | 0.25 | 0.25 | 90.7(49) | 4 | 4 | 0.25–4 |
| Gentamicin | 4.9(5) | 4 | 4 | 14.8(8) | 4 | 16 | 4–16 |
| Rifampin | 0(0) | 1 | 1 | 0(0) | 1 | 1 | 1–1 |
| Ciprofloxacin | 3.9(4) | 1 | 1 | 29.6(16) | 1 | 4 | 1–4 |
| Gatifloxacin | 0(0) | 2 | 2 | 0(0) | 2 | 2 | 2–2 |
| Levofloxacin | 2.9(3) | 2 | 2 | 31.5(17) | 2 | 8 | 2–8 |
| Moxifloxacin | 0(0) | 2 | 2 | 0(0) | 2 | 2 | 2–2 |
| Trimethoprim/Sulfamethoxazole | 25.2(26) | 2 | 4 | 59.3(32) | 4 | 4 | 2–4 |
| Clindamycin | 12.6(13) | 0.5 | 2 | 14.8(8) | 0.5 | 4 | 0.5–4 |
| Azithromycin | 38.8(40) | 2 | 8 | 64.8(35) | 8 | 8 | 2–8 |
| Erythromycin | 47.6(49) | 0.5 | 8 | 68.5(37) | 8 | 8 | 0.5–8 |
| Linezolid | 0(0) | 2 | 2 | 0(0) | 2 | 2 | 2–4 |
| Vancomycin | 0(0) | 2 | 2 | 0(0) | 2 | 4 | 2–16 |
| Chloramphenicol | 7.8(8) | 8 | 8 | 11.1(6) | 8 | 32 | 8–32 |
| Quinupristin/Dalfopristin | 0(0) | 1 | 1 | 0(0) | 1 | 1 | 1–1 |
| Tetracycline | 7.8(8) | 4 | 4 | 9.3(5) | 4 | 4 | 4–16 |
Resistance profiles of 54 MRSE isolates with different staphylococcal cassette chromosome mec (SCCmec) types.
| Antibiotics | Resistant Isolates of SCC | ||||||
|---|---|---|---|---|---|---|---|
| I ( | II + IVb ( | III ( | Iva ( | IVd ( | V ( | NT ( | |
| Penicillin G | 100(1) | 100(1) | 100(4) | 96.4(27) | 66.7(2) | 100(3) | 100(14) |
| Ampicillin | 100(1) | 100(1) | 100(4) | 96.4(27) | 66.7(2) | 100(3) | 100(14) |
| Oxacillin | 100(1) | 100(1) | 75(3) | 89.3(25) | 66.7(2) | 100(3) | 100(14) |
| Gentamicin | 100(1) | 0(0) | 0(0) | 10.7(3) | 33.3(1) | 0(0) | 21.4(3) |
| Rifampin | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Ciprofloxacin | 0(0) | 100(1) | 50(2) | 21.4(6) | 0(0) | 66.7(2) | 35.7(5) |
| Gatifloxacin | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Levofloxacin | 0(0) | 100(1) | 50.0(2) | 25.0(7) | 0(0) | 66.7(2) | 35.7(5) |
| Moxifloxacin | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Trimethoprim/Sulfamethoxazole | 0(0) | 100(1) | 25(1) | 67.9(19) | 66.7(2) | 100(3) | 42.9(6) |
| Clindamycin | 0(0) | 0(0) | 25(1) | 7.1(2) | 0(0) | 0(0) | 35.7(5) |
| Azithromycin | 100(1) | 100(1) | 25(1) | 60.7(17) | 66.7(2) | 66.7(2) | 78.6(11) |
| Erythromycin | 100(1) | 100(1) | 25(1) | 67.9(19) | 66.7(2) | 66.7(2) | 78.6(11) |
| Linezolid | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Vancomycin | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Chloramphenicol | 0(0) | 0(0) | 0(0) | 7.1(2) | 0(0) | 0(0) | 28.6(4) |
| Quinupristin/Dalfopristin | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
| Tetracycline | 0(0) | 100(1) | 25(1) | 7.1(2) | 0(0) | 0(0) | 7.1(1) |
Resistance patterns of MRSE isolates.
| Resistance Patterns | No. of Isol. | % Isol. | SCC | PFGE Type (n) |
|---|---|---|---|---|
| ERY | 2 | 3.7 | IVa(2) | 9(2) |
| SXT | 1 | 1.9 | IVa(1) | 17(1) |
| OXA | 4 | 7.4 | III(1), IVa(1), IVd(1), NT(1) | 1(4) |
| SXT + ERY | 1 | 1.9 | IVd(1) | 1(1) |
| SXT + CIP | 1 | 1.9 | III(1) | 25(1) |
| OXA + TCY | 1 | 1.9 | III(1) | 28(1) |
| OXA + CHL | 1 | 1.9 | NT(1) | 13(1) |
| OXA + ERY | 3 | 5.6 | IVa(1), NT(2) | 16(1), 19(2) |
| OXA + CLI | 2 | 3.7 | IVa(2) | 1(1), 12(1) |
| OXA + SXT | 3 | 5.6 | IVa(3) | 20(1), 23(1), 24(1) |
| OXA + GEN | 1 | 1.9 | IVa(1) | 12(1) |
| OXA + CLI + ERY | 1 | 1.9 | NT(1) | 1(1) |
| OXA + SXT + CHL | 1 | 1.9 | IVa(1) | 17(1) |
| OXA + SXT + ERY | 6 | 11.1 | IVa(5), V(1) | 7(1),9(1),15(1), 7(1), 18(1), 19(1) |
| OXA + CIP + ERY | 1 | 1.9 | IVa(1) | 22(1) |
| OXA + CIP + SXT | 1 | 1.9 | V(1) | 1(1) |
| OXA + GEN + ERY | 1 | 1.9 | I(1) | 12(1) |
| OXA + CLI + ERY + CHL | 3 | 5.6 | NT(3) | 1(3) |
| OXA + SXT + ERY + TCY | 2 | 3.7 | IVa(2) | 11(1), 17(1) |
| OXA + SXT + ERY + CHL | 1 | 1.9 | IVa(1) | 15(1) |
| OXA +SXT + CLI + ERY | 2 | 3.7 | IVa(1), NT(1) | 15(1), 29(1) |
| OXA + CIP + CLI + ERY | 2 | 3.7 | IVa(1), III(1) | 2(1), 10(1) |
| OXA + CIP + SXT + ERY | 5 | 9.3 | IVa(2),V(1), NT(2) | 1(2),8(1),14(1), 26(1) |
| OXA + GEN + SXT + ERY | 1 | 1.9 | IVd(1) | 5(1) |
| OXA + GEN + CIP + SXT | 1 | 1.9 | NT(1) | 3(1) |
| OXA + CIP + SXT + ERY + TCY | 1 | 1.9 | IVb/II(1) | 11(1) |
| OXA + CIP + SXT + CLI + ERY | 1 | 1.9 | IVa(1) | 21(1) |
| OXA + GEN + CIP + SXT + ERY | 2 | 3.7 | IVa(2) | 6(1), 27(1) |
| OXA + GEN + CIP + SXT + ERY + CHL | 1 | 1.9 | NT(1) | 3(1) |
| OXA + GEN + CIP + SXT + ERY + CHL + TCY | 1 | 1.9 | NT(1) | 4(1) |
ERY: erythromycin; SXT: sulfamethoxazole; OXA: oxacillin; CIP: ciprofloxacin; TCY: tetracycline; CHL: chloramphenicol; CLI: clindamycin; GEN: gentamicin.
Figure 1Dendrogram of pulsed-field gel electrophoresis patterns of MRSE isolates. At a Dice similarity index of 79%, 29 PFGE types were identified. The strain number, the SCCmec type, and the PFGE type are indicated at the right of the dendrogram.